Primo Capital invests in MT Ortho, a company specializing in implantable devices for spinal neurosurgery and orthopedics

16 ott 2025 Press Release, MT Ortho

Primo Capital SGR, through its Primo Health fund, has become a significant shareholder in MT Ortho S.r.l., a company based in Aci Sant'Antonio (Catania) operating in the field of implantable devices for spinal neurosurgery and orthopedics. The transaction, which involves a series of capital contributions, is aimed at supporting the company's industrial and international growth.

TRANSACTION DETAILS
The transaction is being carried out by Primo Capital SGR through Primo Health, a private equity fund that invests in small and medium-sized Italian companies in the healthcare sector, with a focus on medical devices, pharmaceuticals, private healthcare services, and animal health. This is the first transaction carried out by the fund, which has raised €65 million to date.
Founded in 2001 and led by Roberto Drago and Gaetano Sorano, MT Ortho is an Italian company active in the design, manufacture, and marketing of innovative implantable devices for spinal neurosurgery, orthopedics, and maxillofacial reconstructive surgery.

In 2024, the Company recorded revenues of approximately €11 million, with growth of 15% expected for 2025. Revenues derive in part from the exclusive distribution, in southern Italy, of products from some of the leading companies in the sector. Looking ahead, the most significant part of turnover will come from the development, production, and sale of devices based on proprietary and patented technology. These devices include trabecular titanium vertebral and cervical cages and a system for repairing vertebral fractures by implanting microspheres, also made of titanium, which are capable of reconstructing the bone structure inside the injured vertebra. In fact, this type of intervention falls within the scope of Regenerative Medicine, one of the most interesting therapeutic areas in medicine. In addition, the company manufactures custom-made prostheses for the repair of severe cranial, maxillofacial, and other types of injuries. The growth rate of turnover for proprietary devices is over 30%.

MT Ortho products are manufactured using a 3D printing process from titanium powders, which give the implantable devices their osteoinductive properties and allow for the creation and innovation of a wide range of products at competitive costs.

The global market for orthopedic devices is estimated at $53 billion in 2024 and is expected to reach over $75 billion by 2033, with an estimated compound annual growth rate (CAGR) of between 4.5% and 6%. Growth in the sector is driven by structural factors such as an aging population, an increase in musculoskeletal disorders, and the spread of innovative technologies such as biocompatible materials, 3D printing, and robotic surgery.

COMMENTS

“MT Ortho fits perfectly into the investment strategy of the Primo Heath fund, which aims to support and accelerate the technological and commercial growth of Italian SMEs in the healthcare sector. In MT Ortho, we found the essential requirements for the success of this type of business: technology aimed at meeting the real needs of the healthcare world, an extensive network within the international medical community, motivation, specific skills, and energy spread across all levels of human resources," comments Carlo Vanoli, General Partner of Primo Health.

"Mt Ortho has always designed highly innovative devices for the treatment of skeletal disorders, both custom-made and mass-produced. The brilliant and now consolidated clinical results compel us to look beyond our borders, first to the EU market and, in the medium term, to the North American market. Hence the need for a financial, technical, strategic, and systemic partnership, all characteristics that are widely found in the spirit and capabilities of Primo Capital. In conclusion, Primo Capital and its Primo Health fund stand out from traditional investment fund models, breaking the mold thanks to a collaborative approach and a rich diversity of skills, elements that are fundamental to achieving what are now common goals," commented Gaetano Sorano and Roberto Drago, President and CEO of MT Ortho.

ADVISORS

Primo Health was assisted by DLA Piper for legal and corporate matters, Grant Thorton for financial and tax due diligence, T8P for ESG matters, Myra Medical for regulatory/IP matters, and TAUW for environmental due diligence.
MT Ortho and its shareholders were assisted by Value Track SIM SpA as financial advisor and by Pavia e Ansaldo for legal and contractual aspects.

The latest news from our network
Follow us on Linkedin.